AAPP submitted comments supporting DEA's proposal to classify tianeptine as a controlled substance, citing its growing misuse, opioid-like effects at high doses, and widespread retail availability despite not being FDA-approved. While supporting stronger federal controls to reduce public access and improve patient safety, AAPP also encouraged the DEA to carefully consider the classification and continue facilitating legitimate research on tianeptine to better understand patterns of use, misuse, and effective treatment strategies.